Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted
Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted
William Blair analysts noted that Carlyle sold some of its shares earlier this summer through smaller transactions. At that time, investors had suggested block trades or secondary transactions for any further sales by Carlyle. Tuesday's announcement aligns with these preferences, which investors may view positively.On Tuesday, QuidelOrtho Corporation (NASDAQ:QDEL) priced the previously announced underwritten secondary offering by Carlyle Partners VI Cayman Holdings of 8.26 million shares.
週二，窺得兒醫藥公司（納斯達克:QDEL）定價了卡萊爾六號凱曼控股之前宣佈的826萬股的次級發行。
The selling stockholder will receive all of the proceeds. The company is not selling any shares.
出售股東將收到所有收益。公司不出售任何股份。
The last reported sale price of QuidelOrtho's common stock on Nov. 19 was $38.58 per share. Goldman Sachs & Co. LLC is acting as the sole underwriter.
窺得兒醫藥普通股11月19日的最近報價爲每股38.58美元。高盛及其附屬公司充當唯一承銷商。
William Blair analysts noted that Carlyle sold some of its shares earlier this summer through smaller transactions. At that time, investors had suggested block trades or secondary transactions for any further sales by Carlyle. Tuesday's announcement aligns with these preferences, which investors may view positively.
威廉·布萊爾（William Blair）分析師指出，卡萊爾在今年夏天早些時候通過較小的交易出售了部分股份。 那時，投資者建議卡萊爾通過大宗交易或次級交易進行進一步出售。 週二的公告符合這些偏好，投資者可能會積極看待。
While some might interpret this move as a lack of confidence in QuidelOrtho's ongoing improvements, the analysts do not share that view.
儘管一些人可能會解釋這一舉動是對窺得兒醫藥持續改善缺乏信心的表現，但分析師並不認同這種觀點。
Instead, they emphasize considering factors like Carlyle's long ownership period, as the firm originally acquired Ortho Clinical in 2014.
相反，他們強調考慮卡萊爾的長揸期等因素，因爲該公司最初於2014年收購了奧萊化驗（Ortho Clinical）。
William Blair analysts write, "We take this as a long-term net-positive for the stock as it removes one of the overhangs that came up in investor conversations around the name."
威廉·布萊爾分析師寫道：「我們認爲這對股票是長期淨利好，因爲它消除了投資者在關於該公司的交談中出現的部分顧慮。」
William Blair reiterates a Market Perform rating.
威廉·布萊爾重申市場表現評級。
Price Action: QDEL stock is down 4.2% at $36.96 at last check Wednesday.
價格走勢：窺得兒醫藥股票最新交易價爲36.96美元，週三最後查看時下跌了4.2%。
- Salesforce Tool Aims To Simplify AI Agent Testing, Deployment
- 賽富時工具旨在簡化人工智能代理的測試和部署
Photo: Shutterstock
Photo: shutterstock
譯文內容由第三人軟體翻譯。
